• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-04-25

  Anlotinib hydrochloride is redefining angiogenesis assays with unmatched multi-kinase selectivity, nanomolar potency, and minimal cytotoxicity. This guide details experimental workflows, protocol parameters, and troubleshooting strategies for leveraging Anlotinib in cutting-edge cancer and vascular research.

• IGFBP2-THBS1 Axis Mediates GH-Induced Bone Growth in ISS

  2026-04-24

  This study uncovers how recombinant human growth hormone (GH) therapy promotes bone growth in idiopathic short stature (ISS) children by modulating the IGFBP2–THBS1–IGF-1 signaling axis. The findings clarify the molecular mechanism behind GH efficacy in ISS, providing a new basis for targeted interventions and research workflows.

• HDAC Inhibitors Suppress NUT Function in NUT Carcinoma Model

  2026-04-24

  Shiota et al. identified diverse histone deacetylase (HDAC) inhibitors as potent repressors of NUT-mediated oncogenic transcription in NUT carcinoma through a high-throughput chemical screen. Their findings provide mechanistic and therapeutic insights, showing that HDAC inhibition disrupts megadomain-driven gene expression and promotes NC cell differentiation, thereby supporting novel strategies for rare squamous carcinoma treatment.

• Optimizing Protein Extraction with Protease and Phosphatase

  2026-04-23

  Unlock uncompromised protein and phosphorylation integrity—especially in sensitive stem cell workflows—using the Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X in ddH2O). This article delivers applied protocols, expert troubleshooting, and actionable insights derived from recent cardiac differentiation research.

• PERK-Dependent JAK1–STAT3 Activation Drives NPC Pyroptosis i

  2026-04-23

  This study elucidates how endoplasmic reticulum stress (ERS) induces pyroptosis in nucleus pulposus cells (NPCs) through PERK/eIF2α/ATF4-mediated JAK1–STAT3 activation, directly linking ERS to inflammation in intervertebral disc degeneration (IDD). The findings highlight the therapeutic potential of targeting the PERK–JAK1–STAT3 axis to mitigate disc cell death and inflammation.

• IWR-1-endo: Potent Wnt Signaling Inhibitor for Biomedical Re

  2026-04-22

  IWR-1-endo is a nanomolar-potency small molecule Wnt signaling inhibitor that antagonizes Wnt/β-catenin signaling by stabilizing Axin-scaffolded destruction complexes. It demonstrates efficacy in colorectal cancer research and regenerative biology, enabling precise inhibition of β-catenin accumulation. Product quality and workflow integration are supported by peer-reviewed data and validated protocols.

• 25-Hydroxycholesterol Drives Immunosuppressive Macrophage Pr

  2026-04-22

  Xiao et al. (2024) uncover how lysosomal 25-hydroxycholesterol (25HC) activates AMPKα-mediated metabolic reprogramming in tumor-associated macrophages (TAMs), bolstering their immunosuppressive phenotype. Their work identifies CH25H and its downstream pathways as actionable targets to enhance anti-tumor immunity and improve responses to checkpoint inhibitors.

• Degarelix Acetate: Precision GnRH Receptor Antagonist Workfl

  2026-04-21

  Degarelix acetate empowers bench scientists with rapid, reproducible suppression of pituitary and androgenic hormones, optimized for both in vitro and in vivo prostate cancer research. This guide translates cutting-edge evidence and aggregation insights into actionable protocols, troubleshooting, and advanced applications.

• Aneugen Mechanisms: Insights from Multi-Target Assay Validat

  2026-04-21

  Bernacki et al. introduce a tiered molecular mechanism assay that discriminates between tubulin stabilizers, destabilizers, and mitotic kinase inhibitors among aneugenic compounds. This study advances genotoxicity profiling by integrating flow cytometry and machine learning, enabling precise classification of molecular targets and supporting more informed drug safety assessment.

• Amitriptyline HCl: Protocols and QC for Neuropharmacology Re

  2026-04-20

  Amitriptyline HCl (SKU B2231) provides high-purity, well-characterized inhibition of several neurotransmitter receptors for in vitro studies of receptor modulation, signal transduction, and neuropharmacology workflows. This reagent is suitable for experimental setups requiring precise control of serotonin, norepinephrine, and related pathways, but is not intended for long-term solution storage or clinical applications.

• Maraviroc (UK-427857): Unlocking CCR5 for Translational Impa

  2026-04-20

  This thought-leadership article explores Maraviroc (UK-427857) as a selective CCR5 antagonist, delving into its mechanistic value in HIV-1 entry inhibition and neuroinflammation modulation. Integrating recent advances in the biology of inflammation in ischemic stroke, it provides strategic, evidence-labeled guidance for translational researchers. The content differentiates itself by bridging virology and neurobiology, offering actionable protocol parameters, and highlighting APExBIO’s Maraviroc as a research-grade benchmark.

• Advanced In Vitro Metrics Refine Cancer Drug Response Evalua

  2026-04-19

  Schwartz's dissertation establishes a rigorous distinction between cell proliferation arrest and cell death when assessing anti-cancer drug responses in vitro. This methodological innovation provides more nuanced data on drug efficacy, with direct implications for optimizing both experimental design and interpretation in cancer research.

• Tacrine-Based Hybrids: Multi-Target Strategies in Alzheimer'

  2026-04-18

  The reviewed study provides a comprehensive analysis of tacrine (tetrahydroaminacrine, THA)-based hybrid molecules as multi-target agents for Alzheimer's disease (AD). By dissecting the pharmacological rationale and design strategies from 2006–2022, it highlights innovations in reducing hepatotoxicity and enhancing cognitive outcomes, offering a technical foundation for new cholinesterase inhibitor development.

• Super-Enhancer Hijacking of LINC01977 Drives LUAD Progressio

  2026-04-17

  Zhang et al. (2022) identify super-enhancer-mediated upregulation of LINC01977 as a key driver of early-stage lung adenocarcinoma (LUAD) progression via the canonical TGF-β/SMAD3 pathway. Their integrative analysis reveals a feedback loop involving tumor-associated macrophages, epigenetic remodeling, and transcriptional coactivators, offering new avenues for targeted epigenetics research.

• 5-Methyl-CTP: Advancing mRNA Synthesis with Enhanced Stabili

  2026-04-16

  5-Methyl-CTP empowers researchers to synthesize mRNA with superior stability and translation efficiency by precisely mimicking natural methylation patterns. Streamline mRNA vaccine and gene expression workflows for robust, reproducible results—especially in demanding translational research and therapeutic development.

14551 records 1/971 page Next 12345 下5页 Last page